Refractory cutaneous pseudolymphoma treated with tapinarof

Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process that histopathologically and/or clinically imitates cutaneous lymphoma. We report the case of a 62-year-old woman with a poorly defined, erythematous plaque with papules on the dorsal nose that had been present for years. This lesion was biopsied as an atypical T-cell infiltrate and was clinically diagnosed as a pseudolymphoma. After unsuccessful treatments with mometasone and tacrolimus, the patient was started on tapinarof cream 1%. After 10 months of treatment, there was clinical improvement of the plaque and papules with only slight residual erythema. Further studies and reports will help elucidate the role of tapinarof as a therapeutic option for pseudolymphoma. Based on its safety profile and promising results in other inflammatory and hyperproliferative disorders, it could be considered in refractory cases.

Authors

Institutions

Publication Details

Journal
Baylor University Medical Center Proceedings
Published
2025-04-09
DOI
https://doi.org/10.1080/08998280.2025.2487381
Citations
1
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
2.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Refractory cutaneous pseudolymphoma treated with tapinarof

Darío Kivelevitch, Emily E. Limmer, Shravya Kichena
1 citations
Baylor University Medical Center Proceedings
Cutaneous lymphoproliferative disorders research
2.00
article

Refractory cutaneous pseudolymphoma treated with tapinarof

Darío Kivelevitch, Emily E. Limmer, Shravya Kichena
article en
1 citations

Abstract

Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process that histopathologically and/or clinically imitates cutaneous lymphoma. We report the case of a 62-year-old woman with a poorly defined, erythematous plaque with papules on the dorsal nose that had been present for years. This lesion was biopsied as an atypical T-cell infiltrate and was clinically diagnosed as a pseudolymphoma. After unsuccessful treatments with mometasone and tacrolimus, the patient was started on tapinarof cream 1%. After 10 months of treatment, there was clinical improvement of the plaque and papules with only slight residual erythema. Further studies and reports will help elucidate the role of tapinarof as a therapeutic option for pseudolymphoma. Based on its safety profile and promising results in other inflammatory and hyperproliferative disorders, it could be considered in refractory cases.

Baylor University Medical Center ProceedingsVol. 38(5)
Texas Tech University (US), Baylor University Medical Center (US), Clarity Water Treatment Systems (Norway) (NO), Texas Tech University Health Sciences Center (US)
Zero hunger
Openalex Percentile: Top 16%
Cutaneous lymphoproliferative disorders research
2.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Refractory cutaneous pseudolymphoma treated with tapinarof — Darío Kivelevitch, Emily E. Limmer, et al. · Baylor University Medical Center Proceedings (2025) | TGRS Research Map | TGRS